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INTRODUTION
Many systemic action drugs can cause acute glaucoma, but si ­
mul taneous bilateral acute angle­closure glaucoma (BAACG) is rare. 
Topiramate is a sulpha­derivative monosaccharide that is used for 
treating epilepsy (1996) and migraine (2004), but other indications 
includes infantile spasms, psychiatric disorders, neuropathic pain, 
weight reduction, tobacco dependence, essential tremor, and 
post­herpetic neuralgia(1). Topiramate blocks voltage­gated sodium 
channels, hyperpolarizes potassium currents, enhances postsynaptic 
gamma­aminobutyric acid receptor activity, suppresses the α­ami ­
no­3­hydroxy­5­methyl­4­isoxazolepropionic acid (AMPA)/kainate 
re ceptor, reduces glutamate excitatory activity and inhibits some 
carbonic anhydrase isoenzimes(2). This drug is rapidly absorbed 
after oral intake and is excreted in urine with a half­life of almost 
24 hours(1). Adverse ophthalmologic events topiramate­related are 
rare, and they generally occur during the first treatment month(3). 
Besides BAACG, other ocular side effects related to topiramate are 
massive choroidal effusion, ocular inflammatory reactions, unilateral 
hemianopsia, neuro­ophthalmologic complications and irreversible 
maculopathy(1,2). The first description of BAACG related to topiramate 
was published in 2001(4) and a systematic 2012 review described 75 
relevant studies concerning topiramate effects on vision. Sixty­fi­
ve small observational studies described the ophthalmologic side 
effects in 84 patients(1). 
The putative mechanism of acute glaucoma and myopia are rela­
ted to uveal effusion, that leads to zonula relaxation, causing anterior 
displacement of the lens­iris diaphragm. As consequence, occurs 
miopization and reduction of anterior camera deepness. Choroidal 
detachment is frequently associated. Some authors suggest that 
acu te myopia is due to the anhydrase carbonic inhibition, lens edema 
and accommodation spasm(5,6).
Topiramate is the leading cause of BAACG in patients under 
the forties and is a potentially blinding disease. The clinical picture 
is reversible if diagnosed and treated precociously and the drug is 
immediately discontinued(4,7­10). The incidence of permanent vision 
loss in topiramate­associated BAACG is 8.1%(6).
CASE PRESENTATION 
A 55­year­old white woman presented with BAACG, one week 
after starting topiramate, 25 mg/day, indicated to migraine preven­
tion. She also had spasmodic torticollis and essential tremor. She 
presented a 4 hours history of sudden blurring of vision, feeling of 
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ABSTRACT
This paper describes a topiramate induced acute bilateral angle­closure glaucoma. 
This rare adverse effect is an idiosyncratic reaction characterized by uveal effusion 
and lens forward displacement, leading to increased intraocular pressure and 
vision loss. We describe a 55 year­old white woman with migraine, spasmodic 
torticollis and essential tremor, who developed bilateral acute angle­closure 
glaucoma, one week after starting topiramate 25 mg/day. She was seen at the 
Ophthalmology Emergency Department of the Fundação João Penido Burnier 
(Campinas, SP, Brazil) with a 4 hours history of blurry vision, ocular pain and bright 
flashes vision. Slit lamp examination revealed moderate conjunctival injection 
and corneal edema, and shallow anterior chambers. Intraocular pressure was 
48 mmHg in both eyes. Fundoscopic examination findings were normal. She 
was treated with timolol, brimonidine, dorzolamide, pilocarpine, prednisone 
acetate eye drops and acetazolamide. One hour after those measures, as the 
intraocular pressure was 30 mmHg, she received a manitol intravenous injection 
and the intraocular pressure normalized. After 24 hours an iridotomy with Yag 
laser was performed. Topiramate was discontinued and she was totally recovered 
after one week.
Keywords: Glaucoma, angle closure/diagnosis; Glaucoma, angle closure/chemi­
cally induced; Anticonvulsants/adverse effects; Intraocular pressure; Uveal diseases/
chemically induced; Case report
RESUMO
Relato de um caso de glaucoma bilateral de ângulo fechado induzido pelo topira ­
mato. Este raro efeito colateral é uma idiosincrasia causada por efusão uveal e 
deslocamento do cristalino para frente, causando aumento da pressão intraocular 
e perda visual. Descrevemos o caso de uma paciente de 55 anos com migrânea, 
torcicolo espasmódico e tremor essencial, que desenvolveu glaucoma bilateral 
de ângulo fechado uma semana após iniciar o uso de topiramato, 25 mg/dia. A 
paciente foi atendida no setor de Emergências Oftalmológicas da Fundação Penido 
Burnier (Campinas, SP, Brasil), com história de 4 horas de embaçamento visual, dor 
ocular e visão de flashes brilhantes. O exame com lâmpada de fenda revelou inje­
ção conjuntival moderada, edema corneano e câmara anterior rasa em ambos os 
olhos. A pressão intraocular era de 48 mmHg bilateralmente e a fundoscopia era 
normal. Foi tratada com colírios de timolol, brimonidina, dorzolamida, pilocarpina 
e acetato de prednisona e acetazolamida via oral. Uma hora após essas medidas, a 
pressão intraocular era 30 mmHg, e a paciente recebeu uma injeção intravenosa de 
manitol, ocorrendo normalização da pressão intraocular após essa medida. Após 
24 horas foi realizada iridectomia com Yag laser. O topiramato foi interrompido e 
ela se recuperou totalmente após uma semana.
Descritores: Glaucoma, ângulo­fechado/diagnóstico; Glaucoma, ângulo­fechado/
quimicamente induzido; Anticonvulsivantes/efeitos adversos; Pressão intraocular; Doen ­
ças uveais/induzidas quimicamente; Relato de caso
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pressure over the eyes and visual flashes perception. On the initial 
examination, the best corrected visual acuities were 0.8 and 0.5 on 
the right eye (OD) and left eye (OS) respectively, with ­2.00 in both 
eyes (BE). The biomicroscopy showed shallow anterior chambers, 
moderate corneal edema and moderate conjunctival injection (Figu­
re 1). The IOPs were 48 mmHg OU. The gonioscopy with and without 
compression revealed a 360o bilateral closed angle and a superior 
180o synechiae indentation. Fundoscopic examination was normal. 
After the diagnosis of BAACG topiramate was immediately discon­
tinued. She was treated with topical 0.5% timolol maleate, 0.15% 
brimonidine tartrate, 2% dorzolamide hydrochloride, 1% prednisolo ­
ne acetate, 1% pilocarpine and 500 mg acetazolamide orally. After 
one hour, the IOP was 30 mmHg OU and intravenous 20% mannitol 
(50 g) was administered. After two hours, the IOP was 18 mmHg in 
both eyes, the symptoms improved and she was discharged home 
with prednisolone acetate, pilocarpine, brimonidine tartrate and 
timolol maleate. By the next morning the patient continued asymp­
tomatic and the visual acuities were 0.8 on the OD and 0.66 on the 
OS. Biomicroscopy showed shallow anterior chambers and there was 
no corneal edema. Gonioscopy revealed sinechiae and a superior 
180o closed angle and IOP was 16 mmHg. An Yag laser iridotomy 
was performed OU because there was risk of total angle closure. She 
was sent home with prednisolone acetate, brimonidine tartrate and 
timolol maleate. After 48 hours, she returned asymptomatic, and 
the best corrected visual acuities were 0.8 OU, without myopic shift. 
The corneal edema disappeared and there was a lens intumescence. 
Gonioscopy revealed synechiae on 180o inferior OU. Fundoscopy 
showed a 0.6 X 0.6 excavation bilaterally. Visual fields were full OU. 
The pachymetry results were 473 µm on the RE and 475 µm on the 
LE. The optical coherence tomography showed a 0.6 x 0.7 excavation 
and there was no optical nerve fiber loss OU. The IOP was 12 mmHg 
in BE, and the iridotomy was patent. The patient was discharged with 
a brimonidine tartrate and timolol maleate prescription. One month 
after, she had no symptoms, the visual acuity returned to normal, and 
the pattern shift visual evoked potentials results were normal.
DISCUSSION
We report the third Brazilian case of BAACG related to topira­
mate, with a favorable outcome(2,10). Our patient symptoms began 
one week after initiating topiramate, accordingly to other previous 
published cases, which visual symptoms initiated during the two 
initial treatment weeks(6,8). Topiramate dosis related to BAACG was 
up to 50 mg in almost 50% of the yet described cases, as occurred 
with this patient(6).
 Ophthalmologic evaluation showed increased IOP, shallow ante­
rior chambers, moderate corneal edema and moderate conjunctival 
injection, signs frequently described in the literature(1,6). This clinical 
picture was acute and bilateral, as commonly seen in other topira­
mate­induced glaucoma reports, and can occur at any age(1,2,10). This 
patient initial treatment was a conventional one for glaucoma, but 
there was no complete IOP normalization until mannitol intravenous 
administration. On the next day, the biomicroscopy showed sine­
chiae and she was treated with a bilateral Yag laser iridotomy because 
those sinechiae could be present previously and then predispose to a 
total angle closure recurrence. Laser or surgical peripheral iridotomy 
was performed on 38% of the BAACG described in the literature, 
but generally this procedure is not indicated, because as the acute 
glaucoma is caused by uveal effusion without pupillary block, a 
pe ripheral iridotomy can aggravate the glaucoma, putting forward 
iris and lens(6). An increased IOP, if maintained for long periods, can 
damage severely the optic nerve and is of paramount importance 
that the glaucoma etiology could be removed. This case illustrates 
the importance of recognizing this entity in a non­ophthalmic setting 
and that intravenous mannitol may be useful in the treatment of the 
condition when it is not responsive to conventional treatment. Thus, 
it was possible a complete visual symptoms normalization, leading to 
recovery of the deepness of the anterior chamber and normalization 
of IOP. 
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